Pharma BD Deal Intelligence
Sanofi acquired Kadmon for $1.9B for US biotech company.
Sanofi to acquire Kadmon Holdings for $9.50 per share in $1.9B deal for Rezurock ROCK2 inhibitor.
Sanofi to develop Kadmon belumosudil for diffuse cutaneous systemic sclerosis after $1.9 billion buyout.
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi acquired Kadmon Holdings for approximately $1.9 billion ($9.50 per share) in an all-cash merger, gaining Rezurock (belumosudil), an FDA-approved first-in-class treatment for chronic graft-versus-host disease (cGVHD), to strengthen its transplant portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Kadmon Holdings Inc. (this deal) | 2021 | $1.9B | 61 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2021 deals · Sanofi SA deals · Immunology deals